Brief: EMA Says CHMP Recommended Not Granting Marketing Authorisation For Leqembi (Lecanemab)
26/07/2024 11:31
July 26 (Reuters) - Biogen Inc BIIB.O
* EMA SAYS CHMP EXTENSIONS OF INDICATION FOR 11 MEDICINES
THAT ARE
ALREADY AUTHORISED IN THE EU INCLUDING AREXVY
* EMA SAYS CHMP RECOMMENDED NOT GRANTING MARKETING
AUTHORISATION
FOR LEQEMBI (LECANEMAB)
* EMA SAYS CHMP RECOMMENDED GRANTING A CONDITIONAL MARKETING
AUTHORISATION FOR IQIRVO (ELAFIBRANOR)
* EMA SAYS CHMP RECOMMENDED NOT GRANTING MARKETING
AUTHORISATION
FOR LEQEMBI (LECANEMAB)
Further company coverage: BIIB.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Ipsen SA
See all newsFulcrum falls after discontinuing sickle cell drug program
Fulcrum falls after discontinuing sickle cell drug program
Fulcrum scraps sickle cell drug program after FDA raises cancer-risk concerns
Fulcrum Therapeutics falls after scrapping sickle cell drug development
Brief: Ipsen's IQIRVO Shows Meaningful Fatigue Improvements In Moderate-To-Severe PBC Patients